Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Gold Prices Extend Losses as Strong Dollar and Fed Uncertainty Weigh on Markets 
Google Proposes Ad Tech Changes to Address EU Antitrust Penalty 
New York Weighs Corporate Tax Hike as Budget Gap Looms 
South Korea, U.S. Finalize New Trade and Security Agreements 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Saudi Arabia Scales Back Expat Salary Premiums as Vision 2030 Priorities Shift 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
South Korea Faces Rising Industrial Accidents as President Lee Pushes New Safety Reforms 
Nomura Probes Potential Profit Inflation in India Fixed-Income Unit 
Thailand, U.S. to Continue Trade Deal Talks Despite Cambodia Border Tensions 
Australia Welcomes Trump’s Removal of U.S. Beef Tariffs as Boost for Producers 
Asia Markets Remain Cautious as Investors Await U.S. Data and AI-Driven Earnings 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Alphabet Shares Surge After Berkshire Hathaway Reveals $4.3 Billion Stake 
GSK and Eli Lilly Announce Billions in U.S. Manufacturing Investments Amid Tariff Concerns 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
